BioSpace News Archive

AEON Biopharma, Inc. and Priveterra Acquisition Corp. announced the filing of Form S-4 Registration Statement with the U.S. Securities and Exchange Commission regarding the recently announced business combination between the two companies.

Janux Therapeutics, Inc. announced that the Company has submitted the investigational new drug application for JANX008 to the U.S. Food and Drug Administration, an EGFR-TRACTr in development for the treatment of EGFR-expressing solid tumors, including non-small cell lung cancer, colorectal cancer, renal cell carcinoma, and squamous cell carcinoma of the head and neck.

Clene Inc. and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company announced topline study results from its Phase 2 investigational trial with CNM-ZnAg, an ionic solution of zinc and silver, for the treatment of non-hospitalized acutely symptomatic participants infected with COVID-19.

Hologic, Inc. announced that the Company will present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023, at 1:30 p.m. Pacific Time.

ImmunoGen, Inc., a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, announced that Mark Enyedy, President and CEO, will present at the upcoming 41st Annual J.P. Morgan Healthcare Conference in San Francisco, CA. The presentation is scheduled for 3:45pm PT on January 10, 2023.

Tiziana Life Sciences Ltd, a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases announces its interim results for the six months ended 30 June 2022.

Minerva Surgical, Inc. announced that it has entered into a share purchase agreement for the sale of 146,627,565 shares of its common stock in a private placement, led by Accelmed, with participation by New Enterprise Associates, at an offering price of $0.2046 per share.

RELIEF THERAPEUTICS Holding SA, announced that it has filed Amendment No. 2 to its Registration Statement on Form F-1 under the Securities Act of 1933 with the U.S. Securities and Exchange Commission relating to a proposed offering of its ordinary shares in the form of American Depositary Shares.

Catalyst Biosciences, Inc. and GNI Group Ltd. announced that the parties have signed definitive agreements for the sale and purchase of GNI’s proprietary new chemical entity F351 program.

Spectrum Pharmaceuticals announced that on December 27, 2022, Spectrum’s Board of Directors granted an aggregate of 206,059 inducement restricted stock units to commercial non-executive employees who were hired specifically for the launch of ROLVEDON.